Atacicept 25 mg ( DrugBank: Atacicept )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
66	IgA nephropathy	2

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00853762 (ClinicalTrials.gov)	March 2009	26/2/2009	Atacicept in Multiple Sclerosis Extension Study, Phase II	An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)	Relapsing Multiple Sclerosis	Drug: Atacicept 25 mg;Drug: Atacicept 75 mg;Drug: Atacicept 150 mg	EMD Serono	Merck KGaA	Terminated	18 Years	60 Years	All	74	Phase 2	United States;Australia;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;New Caledonia;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom

66. IgA nephropathy

Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-183956	21/2/2017	14/05/2018	A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy	A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy	IgA Nephropathy	Intervention name : Atacicept25mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks. Intervention name : Atacicept75mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks. Intervention name : Atacicept25mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks. Intervention name : Atacicept75mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks. Intervention name : Atacicept150mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks.	Merck Biopharma Co., Ltd.	NULL	complete	20		BOTH	60	Phase 2	Japan, Europe
2	NCT02808429 (ClinicalTrials.gov)	January 31, 2017	16/6/2016	Efficacy and Safety of Atacicept in IgA Nephropathy	A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy	IgA Nephropathy	Drug: Placebo;Drug: Atacicept 25 mg;Drug: Atacicept 75 mg	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Completed	18 Years	N/A	All	16	Phase 2	United States;Japan;United Kingdom;Germany